MedTrace Logo

Bovine Colostrum in Prevention of Necrotizing Enterocolitis and Sepsis in Very Low Birth Weight Neonates

NCT04886674 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2021-05-14

No results posted yet for this study

Summary

Primary Aim: The aim of this study is to investigate the efficacy of bovine colostrum in prevention of necrotizing enterocolitis (NEC) and sepsis in very low birth weight (VLBW) infants.

Secondary Aim: To improve outcomes of neonatal sepsis and NEC in the pe-terrms and to decrease their hospital stay.

Conditions

  • NEC

Interventions

DIETARY_SUPPLEMENT

bovine colostrum

The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for \< 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
1 Day
Max Age
5 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-06-30
Completion
2022-07-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04886674 on ClinicalTrials.gov